Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...
Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO...
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...
Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival...
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.